In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

The stock's fall snapped a seven-day winning streak.

The company generated free cash flow of $722 million in Q4 and $2.7 billion for the year. Biogen issued downside guidance for 2025 with an EPS forecast between $15.25 to $16.25 versus $16.33.

Stoke will receive $165m upfront from Biogen upon completion of the transaction. The company is eligible for up to $385m in development and commercial milestone payments, plus tiered royalties on ...

The Green Party's new logo is an emoji. The federal party unveiled its new brand, a green dot, on Tuesday on Parliament Hill, possibly weeks before a snap federal election. "The great thing about ...

Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol ... referencing the first product from the company that she sent to friends last year. "But there are so many more ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ:STOK) have ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ ...

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...

Biogen on Tuesday agreed to pay $165 million upfront for exclusive rights to sell the drug, called zorevunersen, outside the U.S., Canada and Mexico. The company also agreed to split external ...